Friday Health Plans Achieves 400% Membership Growth During Latest Open Enrollment Period for Health Insurance

Enrollment in Friday Health Plans, a health insurance carrier created for the individual and family market, grew…

WeHealth™ Digital Medicine and BioSerenity Initiate a New Phase to Accelerate Cardioskin™ Commercialization

WeHealth™ Digital Medicine, Servier Group’s e-health division, and BioSerenity, today announced that BioSerenity acquired the global…

The Valens Company Submits Site Evidence Package to Health Canada for Manufacturing Facility in Greater Toronto Area

The Valens Company” or “Valens“, a leading manufacturer of cannabis products, today announced that it has submitted…

Genetic Testing Billing Expert Michael F. Arrigo Releases Report Genetic Test Billing Practices, Ethics, Safety and Accuracy, Anti-Discrimination, Privacy

No World Borders, Inc. announced that genetic test billing expert Michael F. Arrigo published findings regarding insurance utilization,…

Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41

Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D…

CTA intros new trustworthiness standard for healthcare AI

The Consumer Technology Association on Wednesday unveiled a new ANSI-accredited standard that it says represents the…

Volpara Health acquires fellow breast cancer prevention company CRA Health

Volpara Health, a maker of artificial intelligence breast-cancer-screening products, has acquired CRA Health, a breast cancer…

Using natural language processing to unlock SDOH in unstructured EHR data

Medical care is estimated to account for only 10-20% of healthcare outcomes. As a result, healthcare…

Experts underestimated EHRs’ impact on burnout after HITECH Act

A study published this week in the Journal of the American Medical Informatics Association found that policy experts underestimated the…

Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly’s SURPASS program

Tirzepatide led to significant A1C and body weight reductions from baseline in adults with type 2…